Recognition of the potential of GLP-1 RAs to address obesity-related concerns, along with their potential for enhanced anti-inflammatory and neuroprotective effects, again indicates the importance of additional research on integration of this drug class into the perioperative care of neurosurgical patients. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.